Clinical Trial Update: A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes [Phase 1]

View source ↗

Summary

Phase I study evaluating twice-weekly dosing of MGCD0103 (mocetinostat) in patients with leukemia or myelodysplastic syndromes to assess safety and dosing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• MGCD0103 (mocetinostat) (mocetinostat)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: COMPLETED